D E Griffith

Summary

Affiliation: University of Texas Health Center
Country: USA

Publications

  1. ncbi request reprint Newly described or emerging human species of nontuberculous mycobacteria
    Barbara A Brown-Elliott
    Mycobacteria Nocardia Laboratory, Department of Microbiology, University of Texas Health Center, Tyler, Texas, USA
    Infect Dis Clin North Am 16:187-220. 2002
  2. doi request reprint Bronchiectasis and nontuberculous mycobacterial disease
    David E Griffith
    Pulmonary and Critical Care Division, Department of Medicine, University of Texas Health Science Center, Tyler, 75708, USA
    Clin Chest Med 33:283-95. 2012
  3. doi request reprint Therapy of refractory nontuberculous mycobacterial lung disease
    David E Griffith
    University of Texas Health Science Center, Tyler, Tyler, Texas 75708, USA
    Curr Opin Infect Dis 25:218-27. 2012
  4. ncbi request reprint Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study
    David E Griffith
    Department of Specialty Care, University of Texas Health Center, Tyler, TX 75708, USA
    Clin Infect Dis 37:1178-82. 2003
  5. ncbi request reprint Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease
    David E Griffith
    The University of Texas Health Center, Department of Medicine, 11937 U S Hwy 271, Tyler, TX 75708, USA
    Am J Respir Crit Care Med 174:928-34. 2006
  6. ncbi request reprint Therapy of nontuberculous mycobacterial disease
    David E Griffith
    University of Texas Health Center at Tyler, Tyler, Texas 75708, USA
    Curr Opin Infect Dis 20:198-203. 2007
  7. ncbi request reprint Management of disease due to Mycobacterium kansasii
    David E Griffith
    Department of Medicine, University of Texas Health Center, 11937 US Highway 271, Tyler, TX 75708 3154, USA
    Clin Chest Med 23:613-21, vi. 2002
  8. ncbi request reprint Diagnosing nontuberculous mycobacterial lung disease. A process in evolution
    David E Griffith
    Clinical Tuberculosis Services, University of Texas Health Center, Tyler, Texas, USA
    Infect Dis Clin North Am 16:235-49. 2002
  9. ncbi request reprint Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease
    David E Griffith
    Professor of Medicine, University of Texas Health Center, 11937 U S Highway 271, Tyler, TX 75708, USA
    Am J Respir Crit Care Med 172:250-3. 2005
  10. doi request reprint Nontuberculous mycobacterial lung disease
    David E Griffith
    University of Texas Health Sciences Center, Tyler, 11937 U S Hwy 271, Tyler, Texas, USA
    Curr Opin Infect Dis 23:185-90. 2010

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Newly described or emerging human species of nontuberculous mycobacteria
    Barbara A Brown-Elliott
    Mycobacteria Nocardia Laboratory, Department of Microbiology, University of Texas Health Center, Tyler, Texas, USA
    Infect Dis Clin North Am 16:187-220. 2002
    ..The clinician must learn about these new pathogens to recognize them clinically and assist the laboratory in their recovery...
  2. doi request reprint Bronchiectasis and nontuberculous mycobacterial disease
    David E Griffith
    Pulmonary and Critical Care Division, Department of Medicine, University of Texas Health Science Center, Tyler, 75708, USA
    Clin Chest Med 33:283-95. 2012
    ..Essentially all NTM patients have bronchiectasis, so optimal overall patient management requires successful therapeutic strategies for both NTM infection and bronchiectasis...
  3. doi request reprint Therapy of refractory nontuberculous mycobacterial lung disease
    David E Griffith
    University of Texas Health Science Center, Tyler, Tyler, Texas 75708, USA
    Curr Opin Infect Dis 25:218-27. 2012
    ....
  4. ncbi request reprint Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study
    David E Griffith
    Department of Specialty Care, University of Texas Health Center, Tyler, TX 75708, USA
    Clin Infect Dis 37:1178-82. 2003
    ..0 months. Clarithromycin- and rifampin-containing regimens offer the possibility of effective short-course and intermittent treatment of M. kansasii lung disease...
  5. ncbi request reprint Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease
    David E Griffith
    The University of Texas Health Center, Department of Medicine, 11937 U S Hwy 271, Tyler, TX 75708, USA
    Am J Respir Crit Care Med 174:928-34. 2006
    ..The clinical features and outcome of macrolide-resistant Mycobacterium avium complex (MAC) lung disease are not known...
  6. ncbi request reprint Therapy of nontuberculous mycobacterial disease
    David E Griffith
    University of Texas Health Center at Tyler, Tyler, Texas 75708, USA
    Curr Opin Infect Dis 20:198-203. 2007
    ....
  7. ncbi request reprint Management of disease due to Mycobacterium kansasii
    David E Griffith
    Department of Medicine, University of Texas Health Center, 11937 US Highway 271, Tyler, TX 75708 3154, USA
    Clin Chest Med 23:613-21, vi. 2002
    ..Short course and intermittent regimens for treating M kansaii disease show promise but are not yet recommended for routine use...
  8. ncbi request reprint Diagnosing nontuberculous mycobacterial lung disease. A process in evolution
    David E Griffith
    Clinical Tuberculosis Services, University of Texas Health Center, Tyler, Texas, USA
    Infect Dis Clin North Am 16:235-49. 2002
    ..Perhaps the 1990 ATS statement was correct. The problem is not diagnosing patients with NTM lung disease, the problem is deciding what to do with them after they are diagnosed...
  9. ncbi request reprint Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease
    David E Griffith
    Professor of Medicine, University of Texas Health Center, 11937 U S Highway 271, Tyler, TX 75708, USA
    Am J Respir Crit Care Med 172:250-3. 2005
    ..All patients with EMB ocular disease returned to baseline ocular status after discontinuation of EMB. Intermittent EBM administration was associated with less ocular toxicity than daily EMB administration in this patient population...
  10. doi request reprint Nontuberculous mycobacterial lung disease
    David E Griffith
    University of Texas Health Sciences Center, Tyler, 11937 U S Hwy 271, Tyler, Texas, USA
    Curr Opin Infect Dis 23:185-90. 2010
    ..There is increasing awareness that nontuberculous mycobacteria (NTM) lung diseases are becoming more prevalent. Nontuberculous mycobacterial diseases could legitimately be seen as an emerging public-health threat...
  11. ncbi request reprint Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex
    D E Griffith
    Department of Medicine, University of Texas Health Center, Tyler, TX 75708, USA
    Clin Infect Dis 30:288-92. 2000
    ..Intermittent (3 times per week) administration of clarithromycin appears to be as effective as daily administration in effecting sputum conversion in pulmonary MAC disease...
  12. ncbi request reprint Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease
    D E Griffith
    Department of Medicine, and the Center for Pulmonary and Infectious Disease Control, The University of Texas Health Center, Tyler, TX 75708 3154, USA
    Clin Infect Dis 32:1547-53. 2001
    ..There were no statistically significant differences in outcome between the 3 regimens. These studies demonstrate the effectiveness of daily and t.i.w. regimens containing azithromycin for treatment of MAC lung disease...
  13. ncbi request reprint Risk-benefit assessment of therapies for Mycobacterium avium complex infections
    D E Griffith
    Center for Pulmonary Infectious Disease Control, The University of Texas Health Center at Tyler, 75708, USA
    Drug Saf 21:137-52. 1999
    ..It is to be hoped that even better drugs that are more active against MAC and are associated with less toxicity and drug-drug interactions will be introduced in the future...
  14. ncbi request reprint The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages
    A Kurdowska
    Department of Biochemistry, University of Texas Health Center at Tyler, Tyler, 11937 US Highway 271, TX 75708 3154, USA
    J Antimicrob Chemother 47:867-70. 2001
    ..Our findings suggest that azithromycin and clarithromycin may alter IL-8 production, thus enhancing the clinical effectiveness of these antibiotics...
  15. ncbi request reprint Clearance of proteins from the air spaces following cardiogenic edema in sheep
    B T Peterson
    Department of Cell Biology, University of Texas Health Center at Tyler 75710, USA
    Exp Lung Res 24:41-56. 1998
    ..We conclude that insights about mechanisms of clearance of edema fluid obtained from studies of clearance of instilled fluid are valid in cardiogenic edema, but the time course of the clearance differs between the two models...
  16. ncbi request reprint Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis
    Richard J Wallace Jr
    Department of Microbiology, University of Texas Health Center at Tyler, Tyler, TX 75708, USA
    J Infect Dis 186:266-73. 2002
    ..No late isolates were macrolide resistant. Thus, relapses of MAC lung disease with these macrolide regimens are unusual, and most infections after completing therapy resulted from new strains in patients with nodular bronchiectasis...
  17. doi request reprint NKG2D-dependent IL-17 production by human T cells in response to an intracellular pathogen
    Padmaja Paidipally
    Departments of Microbiology, University of Texas Health Center, Center for Pulmonary and Infectious Disease Control, Tyler, TX 75708, USA
    J Immunol 183:1940-5. 2009
    ..We conclude that binding of NKG2D to UL-16 binding protein (ULB)1 contributes to IL-23-dependent IL-17 production by CD4(+) cells in human M. tuberculosis infection...
  18. ncbi request reprint Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor
    Ankita Garg
    Center for Pulmonary and Infectious Disease Control, University of Texas Health Center, 11937 U S Highway 271, Tyler, TX 75708, USA
    J Immunol 177:6192-8. 2006
    ..ELISA and Far Western blotting showed that recombinant vimentin bound to a NKp46 fusion protein. These results indicate that vimentin is involved in binding of NKp46 to M. tuberculosis H37Ra-infected mononuclear phagocytes...
  19. ncbi request reprint Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium
    Ramakrishna Vankayalapati
    Center for Pulmonary and Infectious Disease Control, University of Texas Health Center, Tyler 75708, USA
    J Immunol 175:4611-7. 2005
    ..tuberculosis-infected mononuclear phagocytes, and that ULBP1 on infected cells is the major ligand for NKG2D. Furthermore, TLR2 contributes to up-regulation of ULBP1 expression...
  20. ncbi request reprint The CD14 receptor does not mediate entry of Mycobacterium tuberculosis into human mononuclear phagocytes
    Homayoun Shams
    Center for Pulmonary and Infectious Disease Control, University of Texas Health Center, 11937 U S Highway 271, Tyler, TX 75708 3154, USA
    FEMS Immunol Med Microbiol 36:63-9. 2003
    ..tuberculosis; (2) M. tuberculosis infection upregulates CD14 expression on mononuclear phagocytes, and this may facilitate the pathogen's capacity to modulate the immune response...
  21. ncbi request reprint Diagnosis of nontuberculous mycobacterial infections
    Barbara A Brown-Elliott
    Department of Microbiology, University of Texas Health Center, 11937 US Hwy 271, Tyler, TX 75708, USA
    Clin Lab Med 22:911-25, vi. 2002
    ..This article discusses how laboratory results are applied by clinicians, and some of the difficulties and controversies regarding the diagnosis of NTM disease after the laboratory work is complete...
  22. ncbi request reprint Interleukin-1-mediated release of interleukin-8 by asbestos-stimulated human pleural mesothelial cells
    D E Griffith
    Department of Medicine, University of Texas Health Center, Tyler 75710
    Am J Respir Cell Mol Biol 10:245-52. 1994
    ..We conclude that HPMC release IL-8 in response to asbestos stimulation and that the response is, in part, mediated by IL-1, mainly in the form of IL-1 alpha...
  23. ncbi request reprint Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex
    R Vankayalapati
    Center for Pulmonary and Infectious Disease Control, University of Texas Health Center, Tyler, Texas, USA
    J Infect Dis 183:478-84. 2001
    ..Our findings suggest that IFN-gamma, TNF-alpha, and IL-12 contribute to protection against MAC, whereas IL-10 is immunosuppressive...
  24. ncbi request reprint T cells enhance production of IL-18 by monocytes in response to an intracellular pathogen
    R Vankayalapati
    Center for Pulmonary and Infectious Disease Control, University of Texas Health Center, 11937 US Highway 271, Tyler, TX 75708, USA
    J Immunol 166:6749-53. 2001
    ..These findings suggest that activated T cells can contribute to the initial immune response by augmenting IL-18 production by monocytes in response to an intracellular pathogen...
  25. ncbi request reprint Pulmonary disease caused by rapidly growing mycobacteria
    Charles L Daley
    Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Clin Chest Med 23:623-32, vii. 2002
    ..The most common causes of pulmonary disease are Mycobacterium abscessus and Mycobacterium fortuitum. This article reviews the management of patients with lung disease caused by RGM...
  26. ncbi request reprint An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
    David E Griffith
    Am J Respir Crit Care Med 175:367-416. 2007
  27. ncbi request reprint Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis
    David E Griffith
    Am J Respir Crit Care Med 167:810-2. 2003
  28. ncbi request reprint Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease
    Phung K Lam
    Division of Pulmonary and Critical Care Medicine, University of California, San Diego, San Diego, CA 92103 8374, USA
    Am J Respir Crit Care Med 173:1283-9. 2006
    ..Objectives: To characterize response to a three-times-weekly (TIW) regimen of clarithromycin, ethambutol, and rifampin...
  29. ncbi request reprint If it isn't something, it's something else
    David E Griffith
    South Med J 99:112-3. 2006
  30. ncbi request reprint Treatment of multidrug-resistant tuberculosis: should you try this at home?
    David E Griffith
    Am J Respir Crit Care Med 169:1082-3. 2004